Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuretinol Acetate in Inherited Retinal Disease (LCA/RP)
NCT04311112Phase 3Withdrawn
- Sponsor
- Retinagenix
- Start
- Dec 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zuretinol in Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), sponsored by Retinagenix. Planned start Dec 2020; status: withdrawn.
02
Drugs
zuretinol
03
Conditions
Leber congenital amaurosis (LCA)retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT04311112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311112.